TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...

NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...

Credit: BrainsWay. The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain. The Food and Drug Administration (FDA) has expanded the ...

The US Food and Drug Administration (FDA) granted 510K clearance to market a new transcranial magnetic stimulation (TMS) device, the MagVita TMS Therapy system from MagVenture, for treatment of adults ...

Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in individuals ages 15 ...

TMS uses electromagnetic induction to stimulate neurons, similar to how a wireless charger transfers energy. The FDA has cleared TMS for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder ...

BURLINGTON, Mass. and JERUSALEM, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BWAY) (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...

83% of patients who complete Transcranial Magnetic Stimulation treatment experience measurable relief and 62% experience full remission of depression symptoms The expanded label positions Neuronetics' ...

This article is sponsored by Harper Clinic, a Utah-based clinic offering FDA-approved TMS therapy for treatment-resistant ...

An electromagnetic therapy for depression shouldn't damage a person's pre-existing implantable cardioverter-defibrillator (ICD), multiple experiments indicated. There was a low risk of ICD damage or ...